Streptococcus pneumoniae has proteins that are attached to its surface by binding to phosphorylcholine of teichoic and lipoteichoic acids. These proteins are known as choline-binding proteins (CBPs). CBPs are an interesting alternative for the development of a cost-effective vaccine, and PspA (pneumococcal surface protein A) is believed to be the most important protective component among the different CBPs. We sought to use CBPs eluted from pneumococci as an experimental vaccine. Since PspA shows variability between isolates, we constructed strains producing different PspAs. We used the nonencapsulated Rx1 strain, which produces PspA from clade 2 (PspA2), to generate a pspA-knockout strain (Rx1 ΔpspA) and strains expressing PspA from clade 1 (Rx1 pspAI) and clade 4 (Rx1 pspA4). We grew Rx1, Rx1 ΔpspA, Rx1 pspAI, and Rx1 pspA4 in Todde-Hewitt medium containing 0.5% yeast extract and washed cells in 2% choline chloride (CC). SDS-PAGE analysis of the proteins recovered by a CC wash showed few bands, and the CBPs PspA and PspC (pneumococcal surface protein C) were identified by mass spectrometry analysis. Subcutaneous immunization of mice with these full-length native proteins without adjuvant led to significantly higher rates of survival than immunization with diluent after an intranasal lethal challenge with two pneumococcal strains and also after a colonization challenge with one strain. Importantly, immunization with recombinant PspA4 (rPspA4) without adjuvant did not elicit significant protection.
protein to phosphorylcholine, avoiding C3 deposition through the classical pathway (15). PspA is composed of an N-terminal α-helical region exposed on the bacterial surface, followed by a proline-rich region and the C-terminal region with the choline-binding domain (20). Hollingshead and collaborators have proposed a classification based on the amino acid divergence of the most variable part of the α-helical region located just before the proline-rich region, the clade-defining region (CDR) (21). Family 1 comprises clades 1 and 2, and family 2 comprises clades 3, 4, and 5. Family 3, which is rarely isolated, comprises clade 6. Since there is less cross-reactivity between families than within families, it has been proposed that a broad-coverage vaccine should be composed of at least one PspA from each of the two major families (22–24). Previous studies have shown that both the α-helical and proline-rich domains of PspA are able to elicit protection (24, 25), but all phase 1 vaccine trials with the PspA antigen have been conducted using only the α-helical domain (11). Although a mixture of α-helical domains should be protective against most PspAs (22), recent evidence suggests that the proline-rich domain of PspA is even more cross-protective (25). Vaccine immunogens should thus probably contain both of these domains. It has also been shown that immunization with more than one pneumococcal protein generally elicits better protection than immunization with either domain alone (26–28). Finally, it has been shown that the use of the recombinant anti-mouse IgG conjugated with peroxidase (Sigma-Aldrich, St. Louis, MO), and detection was performed with ECL Prime Western blotting reagent (GE Healthcare, United Kingdom).

Recovery of CBPs from pneumococci grown in CDM-ET. Strain Rx1 pspA4 was adapted for growth without choline in chemically defined medium (CDM; Gibco-Life Technologies, Carlsbad, CA) containing ethanolamine (CDM-ET) (32). Adaptation was performed as described previously (14). Briefly, cultures grown in Todd-Hewitt medium containing 0.5% yeast extract (THY) were subcultured in CDM containing 0.02% CC and 0.02% ET. The concentration of CC was decreased stepwise from 0.02% to 0.0000002%. Supernatants of overnight cultures were concentrated by using a Vivaspin 50 centrifugal filter unit with a 10-kDa cutoff (Millipore, Billerica, MA) and dialyzed in phosphate-buffered saline (PBS). The protein concentration was determined by the Bradford method (protein assay; Bio-Rad, Hercules, CA), and recovered proteins were analyzed by SDS-PAGE with Coomassie blue staining.

Elution of CBPs from pneumococci grown in THY. Pneumococcal strains Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 were grown in THY to an optical density at 600 nm (OD600) of 0.4. The cultures were centrifuged, and the cell pellets were washed in PBS. CBPs were eluted thr...
using collision-induced dissociation of the three most intense ions from the MS scan. A dynamic peak exclusion was applied to avoid the same m/z being selected for the next 120 s. The resulting fragment spectra were processed using ProteinLynx software (Waters), and pkl* files were created and searched, using the Mascot search engine (Matrix Science, United Kingdom), against the NCBI nr nucleotide database (downloaded on 5 May 2013). The search was restricted to the Bacteria (Eubacteria) taxonomy with a parent and a fragment tolerance of ±1.2 and ±0.6 Da, respectively. The iodoacetamide derivative of cysteine was specified as a fixed modification, whereas oxidation of methionine and deamidation of asparagine and glutamine were specified as variable modifications.

**Immunization of mice.** Five- to 7-week-old female specific-pathogen-free BALB/c and C57BL/6 mice were obtained from the Medical School of the University of São Paulo (FM-USP, São Paulo, Brazil). Proteins were given through the subcutaneous route in saline. Groups of 6 animals were given three doses of 1 µg of proteins without adjuvant at 14-day intervals. Six animals injected only with saline were used as controls. Proteins were eluted from the pneumococci through incubation with 2% CC and were not dialyzed prior to injection. Mice were immunized with 1 µg rPspA4 without adjuvant for comparison of efficacy.

**Measurement of antibodies by ELISA.** Three weeks after the last immunization, mice were individually bled from the retroorbital plexus. Enzyme-linked immunosorbent assay (ELISA) was carried out as described previously in plates coated with 1 µg/ml rPspA1 or rPspA4 (recombinant proteins that include the mature N-terminal α-helical region plus the proline-rich region of a PspA protein from clade 1 or 4, respectively) (30). Goat anti-mouse IgG conjugated with horseradish peroxidase was used as secondary antibody, and the titer was defined as the highest dilution with an A<sub>405</sub> of ≥0.1.

**Antibody binding to whole pneumococci by flow cytometry.** Assays for antibody binding to whole pneumococci were performed with 1% pooled serum as previously described (16). Bacteria were analyzed using a FACSCanto flow cytometer (BD Biosciences, Franklin Lakes, NJ). Ten thousand gated events were acquired and analyzed in fluorescence intensity histograms using FlowJo (version 7.6.1) software.

**Intranasal lethal aspiration and colonization challenges.** *S. pneumoniae* A66.1, ATCC 6303, and 0603 were grown in THY until the OD<sub>600</sub> was 0.4, aliquoted, and kept frozen at –80°C. At 3 weeks after the last immunization, 3 × 10<sup>7</sup> CFU (ATCC 6303) or 10<sup>6</sup> CFU (A66.1) was inoculated in 50 µl into one nostril of BALB/c mice anesthetized through the intraperitoneal (i.p.) route with 200 µl of a 0.2% xylazine–1.0% ketamine mixture. Survival was monitored for 10 days. Animals were monitored twice daily, and lethargic mice were euthanized through CO<sub>2</sub> narcosis. At 3 weeks after the last immunization, 5 × 10<sup>6</sup> CFU (strain 0603) was inoculated in 10 µl into the two nostrils of C57BL/6 mice anesthetized i.p. with 200 µl of a 0.2% xylazine–0.5% ketamine mixture. After 5 days, the animals were euthanized through CO<sub>2</sub> narcosis, and 200 µl of saline was instilled inside the trachea and washed out through the nostrils twice. The total number of CFU in each sample was determined through plating of diluted samples on blood agar plates containing gentamicin (4 µg/ml) by consideration of the recovered volume. BALB/c mice were used for the intranasal lethal challenge and C57BL/6 mice were used for the nasopharyngeal colonization challenge for comparison with published data from studies that used these mouse lineages for each model (30, 34, 35).

**Statistical analysis.** The Fisher exact test was used to compare survival levels between groups, and one-way analysis of variance (ANOVA) with Tukey’s multicomparison test was used to compare antibody titers and the number of CFU recovered in the colonization challenge (GraphPad Prism [version 5] software).

**RESULTS**

**Construction of Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4.** An Sm-resistant Rx1 clone was transformed with the plasmid containing the Janus cassette, generating Rx1 ΔpspA. Transformation of Rx1 ΔpspA with pspA plus the flanking regions of a PspA1-producing strain (St435/96) and of a PspA4-producing strain (St255/00) generated Rx1 pspA1 and Rx1 pspA4, respectively. The correct insertion was confirmed in all strains through PCR with primers annealing at the flanking regions and also with internal primers. Figure 1 shows the results of analysis of the production of PspA through Western blotting. As expected, PspAs with somewhat different molecular masses were observed for Rx1, Rx1 pspA1, and Rx1 pspA4, whereas no product was detected for Rx1 ΔpspA.

**Recovery of CBPs from pneumococci grown in CDM-ET.** Rx1 pspA4 was adapted for growth in chemically defined medium containing ethanolamine (CDM-ET) in place of choline through several culture passages with decreasing concentrations of choline chloride (CC). We grew the adapted Rx1 pspA4 strain overnight in CDM-ET and collected the supernatant for the recovery of CBPs. The supernatant was concentrated, and the proteins were analyzed by SDS-PAGE. Several bands could be observed in the gel stained with Coomassie blue (Fig. 2A). LC-MS/MS analysis of different bands showed the presence of cytosolic proteins and also of proteins described to be surface exposed in the supernatant of CDM-ET, but no CBPs were identified. Even though PspA could be detected through Western blotting (not shown), CBPs were not the major proteins recovered from the supernatant of Rx1 pspA4 grown overnight in CDM-ET. This result could have been due to the long culture period, which could have resulted in cell death and the release of cytoplasmic content to the culture supernatant.

**Recovery of CBPs from pneumococci grown in THY.** Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 were then grown in THY, and CBPs were recovered through incubation in 2% CC. The recovered proteins were examined by SDS-PAGE, and the gel was silver stained (Fig. 2B). Few bands were observed, and there was retention of proteins in the stacking gel, indicating the presence of aggregates. The major bands in the CC washes of Rx1, Rx1 pspA1, and Rx1 pspA4 were analyzed by LC-MS/MS (see Table S2 in the supplemental material). The Rx1 pspA1 CC wash band showed a hit with PspA, while the Rx1 pspA4 CC wash band showed hits with PspA and PspC. The Rx1 CC wash band showed only one peptide with a hit with the flavoprotein NrdI. Western blot analysis showed the recognition of bands in the protein samples obtained from strains Rx1, Rx1 pspA1, and Rx1 pspA4 by anti-rPspA4 serum, but a considerable amount of the protein recovered from Rx1 was retained in the stacking gel (see Fig. S1 in the supplemental material). It is possible that a large part of the CBPs...
from Rx1 was retained as aggregates in the stacking gel. We have attempted to perform MS analysis with the proteins from the stacking gel, but no CBPs were recognized. This result could be due to problems with in-gel trypsin digestion due to protein aggregation.

Immunization with CBPs recovered from pneumococci grown in THY. The proteins recovered from the cultures grown in THY through incubation in 2% CC were used to immunize naive BALB/c mice subcutaneously without the use of any adjuvant (6 animals/group). Sera from animals immunized with the CBPs recovered by CC washes of Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 cultures grown to exponential phase in THY. Bacteria were incubated in 2% CC, and the eluted proteins were analyzed by SDS-PAGE with silver staining. Bands indicated by the numbers 1 to 3 were submitted to LC-MS/MS analysis, and the results are shown in Table S2 in the supplemental material. Numbers to the left of the gels are molecular masses (in kilodaltons).

FIG 2 Recovery of pneumococcal proteins. (A) Proteins were recovered from the supernatant of an Rx1 pspA4 culture grown overnight in CDM-ET. The supernatant was concentrated and analyzed by SDS-PAGE with Coomassie blue staining. (B) Proteins were eluted through a 2% CC wash of Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 cultures grown to exponential phase in THY. Bacteria were incubated in 2% CC, and the eluted proteins were analyzed by SDS-PAGE with silver staining. Bands indicated by the numbers 1 to 3 were submitted to LC-MS/MS analysis, and the results are shown in Table S2 in the supplemental material. Numbers to the left of the gels are molecular masses (in kilodaltons).

FIG 3 Induction of anti-PspA antibodies. Sera from mice immunized with proteins eluted from Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 through a CC wash were analyzed for the induction of anti-rPspA1 (rPspA1) or anti-rPspA4 (rPspA4) antibodies by ELISA. Sera from animals injected only with saline were used as a control. Bars indicate the mean titer plus the standard error. *, statistically significant difference from the results obtained with saline (P < 0.05, one-way ANOVA with Tukey’s multicomparison test).
Challenge of immunized mice intranasally with live pneumococci. Next, immunized BALB/c mice were intranasally challenged with a lethal dose of A66.1 (PspA2) or ATCC 6303 (PspA5), and survival was analyzed (Table 1). Mice immunized with the CBPs recovered by CC washes of Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 showed statistically significantly higher rates of survival after challenge with A66.1 than animals injected with saline. Mice immunized with the CBPs recovered by CC washes of Rx1 ΔpspA and Rx1 pspA4 also showed statistically significantly higher rates of survival after challenge with ATCC 6303 than animals injected with saline.

Intranasal challenge of mice in a pneumococcal carriage model. Proteins recovered from the cultures grown in THY by elution of pneumococci with CC were also used to immunize C57BL/6 mice subcutaneously without adjuvant in order to evaluate protection against a colonization challenge model with strain 0603 (PspA1). Figure 5 shows the numbers of CFU recovered from the nasopharynx of mice 5 days after challenge. Only the group of animals immunized with CBPs from Rx1 pspA1 showed a significantly lower colonization density than animals immunized with saline. In most prior studies, protection against colonization was seen after immunization with recombinant proteins and a mucosal adjuvant related to cholera toxin (28). In the present studies, the reduction in colonization that has been observed was detected with subcutaneous immunization and in the absence of adjuvant.

DISCUSSION

A mixture of CBPs containing full-length native PspA as the major antigen is an interesting alternative for a broad-coverage vaccine formulation with a low production cost. We evaluated the recovery of CBPs from the supernatant of cultures grown overnight in CDM-ET and from CC washes of cultures grown to exponential phase in complete medium. MS analysis showed the presence of cytosolic proteins and also of proteins described to be surface exposed in the supernatant of CDM-ET, but no CBPs were identified. Pneumococci grown in chemically defined medium without choline were described to grow in long chains and not to undergo autolysis (14, 37, 38), but we cannot rule out the possibility of cell death and lysis during the overnight growth under our culture conditions. On the other hand, CC washes contained few bands by SDS-PAGE analysis, and the major ones were identified of survival after challenge with ATCC 6303 than animals injected with saline.

Intranasal challenge of mice in a pneumococcal carriage model. Proteins recovered from the cultures grown in THY by elution of pneumococci with CC were also used to immunize C57BL/6 mice subcutaneously without adjuvant in order to evaluate protection against a colonization challenge model with strain 0603 (PspA1). Figure 5 shows the numbers of CFU recovered from the nasopharynx of mice 5 days after challenge. Only the group of animals immunized with CBPs from Rx1 pspA1 showed a significantly lower colonization density than animals immunized with saline. In most prior studies, protection against colonization was seen after immunization with recombinant proteins and a mucosal adjuvant related to cholera toxin (28). In the present studies, the reduction in colonization that has been observed was detected with subcutaneous immunization and in the absence of adjuvant.

### TABLE 1 Survival of mice after challenge with A66.1 (PspA2) and ATCC 6303 (PspA5)

| Immunogen | A66.1 | ATCC 6303 |
|-----------|-------|-----------|
|           | No. of animals alive/total | % survival | No. of animals alive/total | % survival |
| saline    | 1/12 8 | 0/12 0 | 0/12 0 |
| Rx1ΔpspA  | 12/12 100 | <0.0001 | 1/12 8 | 1.0000 |
| Rx1 pspA1 | 10/12 83 | 0.0006 | 5/12 42 | 0.0373 |
| Rx1 pspA4 | 9/12 75 | 0.0028 | 4/12 33 | 0.0932 |
| rPspA4    | 11/12 92 | 0.0001 | 7/12 58 | 0.0046 |

*P values by comparison with the results for the saline group (two-sided Fisher exact test).

Immunization with CBP eluted from the indicated strain with 2% choline chloride.

The comparison of protection elicited by rPspA4 and a choline chloride eluate of Rx1 pspA4 was significant at *P* values of 0.027 and 0.15 by the two-sided Fisher exact test for A66.1 and ATCC 6303 challenge, respectively.

Mice were immunized with the indicated immunogens in saline in the absence of any adjuvant. Survival was monitored for 10 days, and the numbers of mice that survived in each group were recorded. Results are pooled data from two independent experiments.
to be PspA and PspC, as expected. Previous work has evaluated the supernatant of cultures grown to exponential phase in the absence of choline and with supplementation with ethanolamine or putrescine, but MS analysis was not performed and only challenge strains of the type 3 capsular type were examined (38, 39).

We thus used CBPs recovered by the CC washes from strains producing PspA2 (Rx1), PspA1 (Rx1 pspA1), and PspA4 (Rx1 pspA4) or lacking pspA (Rx1 ΔpspA) to immunize mice without adjuvant. The use of the nonencapsulated Rx1 strain rules out any influence of polysaccharide contamination in the preparations. Sera from mice immunized with CBPs from Rx1, Rx1 pspA1, and Rx1 pspA4 recognized rPspA1 and rPspA4 by ELISA. When the binding of antibodies to intact pneumococci was analyzed by flow cytometry, there was better binding to bacteria producing PspA from the same clade as the strain used to recover the CBPs. Furthermore, immunization with CBPs from Rx1, Rx1 ΔpspA, Rx1 pspA1, and Rx1 pspA4 elicited protection against a lethal challenge with a PspA2-producing strain, whereas immunization with CBPs from Rx1 ΔpspA and Rx1 pspA4 elicited protection against a lethal challenge with a PspA5-producing strain. Thus, in agreement with our data showing cross-protection through immunization with CBPs from the same clade as the strain used to recover the CBPs. These results are in agreement with previous data showing that PspA is the main protective component but other CBPs can contribute to protection (14). It should be noted that recombinant PspA4, which lacks the choline-binding domain, did not elicit protection in the absence of adjuvant, an illustration of the greater vaccine potential of CC eluates containing full-length molecules than the vaccine potential of rPspA.

When subcutaneously immunized mice were challenged with a PspA1-producing strain intranasally, only immunization with CBPs from Rx1 pspA1 elicited protection against colonization, indicating that clade-specific immunization might be required to elicit protection against carriage, whereas broad cross-protection against fatal challenge was observed. The findings of these studies are in contrast to those of earlier studies using rPspA to protect against carriage, where intranasal immunization and a mucosal adjuvant were normally used (28).

CBPs can thus induce protection in the absence of adjuvants, while rPspA is known to require the use of adjuvants, such as alum and the cholera toxin B subunit, to elicit protection against lethal and colonization challenges (27, 28, 30). This finding suggests that the full-length CBPs exhibit more protective efficacy than the recombinant N-terminal portions of CBPs, which invariably require adjuvant to elicit strong protective responses. Importantly, a vaccine formulation based on CBPs could have a low production cost and require few steps to recover the proteins from the pneumococcal culture. Since we observed possible PspA clade-specific protection against colonization, the use of CBPs obtained from strains producing PspA from family 1 and family 2 is still advisable to attain broad protection and avoid the emergence of vaccine escape mutants.

Other vaccine formulations currently being evaluated by several groups include multiple antigens of pneumococci (11). One advantage of this approach is that selective pressure would be on multiple antigens, making the emergence of vaccine escape mutants a rare event. One of the most promising formulations currently in clinical trials is composed of an inactivated nonencapsulated whole-cell vaccine, which was shown to induce protection against nasal colonization with a variety of pneumococcal serotypes in mice (40), as well as against a lethal challenge with a serotype 3 strain in rats (41). The present studies confirm that a formulation based on CBPs is also an interesting alternative for a pneumococcal vaccine based on multiple antigens, since it would comply with the requirements of low cost and induction of protection against different pneumococcal strains and would be focused on surface antigens.

ACKNOWLEDGMENTS

We are grateful to Jorge M. C. Ferreira for the flow cytometry analysis. This work was supported by CNPq (302070/2011-7 and 472253/2012-3), FAPESP (2011/06853-2), and the Fundação Butantan (Brazil).

REFERENCES

1. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine
13. Shaper, 14. Briles DE.

11. Mukerji

February 2015 Volume 22 Number 2 cvi.asm.org

12. Tu, 17. 18. Pribyl, Perez-Dorado

PATH. 6.

72: pneumococcal surface. Infect Immun

1996. PspA, a protection-eliciting pneumococcal protein: immunogenic-

http://dx.doi.org/10.1007/s00018-012-1234-8.

pneumococcal protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182:1694–1701. http://dx.doi.org/10.1086/376502.

Weiser JN, Szalai AJ, Briles DE. 2000. Immunization of healthy adults with a single recombinant pneumo-

coccal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743–1754. http://dx.doi.org/10.1016/S0264-410X(99)00530-7.

Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A. 2000. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 19(Suppl 1):S87–585. http://dx.doi.org/10.1016/S0264-410X(99)00028-1.

Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Benjamin WH, Jr. 2003. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188:339–348. http://dx.doi.org/10.1086/376571.

Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, Virolainen A, Swiatlo E, Hollingshead SK. 2000. Intranasal immunization of mice with a mixture of the pneumococcal proteins PspA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 68:796–800. http://dx.doi.org/10.1128/IAI.68.5.796-800.2000.

Brooks-Walter A, Briles DE, Hollingshead SK. 1999. The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun 67:6533–6542.

Moreno AT, Oliveira ML, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly J, Briles DE.

Choline-Binding Proteins as Pneumococcal Vaccine

http://dx.doi.org/10.1371/journal.pone.0010863.

Hanna SL, Sherman NE, Kinter MT, Goldberg JB. 2000. Comparison of proteins expressed by Pseudomonas aeruginosa strains representing ini-
tial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography-tandem mass spectrometry. Microbiology 146(Pt 10):2495–2508.

Olivera ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, Santos FL, Sakauchi MA, Takata CS, Higashi HG, Raw I, Kubrusly FS, Ho PH. 2010. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 5:e10863. http://dx.doi.org/10.1371/journal.pone.0010863.

Downloaded from http://cvi.asm.org on July 20, 2018 by guest
35. Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN. 2010. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (pneumococcal surface protein A). Microb Pathog 48:205–213. http://dx.doi.org/10.1016/j.micpath.2010.02.009.

36. Sorensen UB, Henrichsen J, Chen HC, Szu SC. 1990. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods. Microb Pathog 8:325–334. http://dx.doi.org/10.1016/0882-4010(90)90091-4.

37. Yother J, White JM. 1994. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol 176:2976–2985.

38. Ware D, Watt J, Swiatlo E. 2005. Utilization of putrescine by Streptococcus pneumoniae during growth in choline-limited medium. J Microbiol 43:398–405.

39. Swiatlo E, Champlin FR, Holman SC, Wilson WW, Watt JM. 2002. Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect Immun 70:412–415. http://dx.doi.org/10.1128/IAI.70.1.412-415.2002.

40. Malley R, Morse SC, Leite LC, Areas AP, Ho PL, Kubrusly FS, Almeida IC, Anderson P. 2004. Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant. Infect Immun 72:4290–4292. http://dx.doi.org/10.1128/IAI.72.7.4290-4292.2004.

41. Malley R, Lipsitch M, Stack A, Saladino R, Fleisher G, Pelton S, Thompson C, Briles D, Anderson P. 2001. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 69:4870–4873. http://dx.doi.org/10.1128/IAI.69.8.4870-4873.2001.